Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
RAVANDI-KASHANI, FARHAD
One or more keywords matched the following items that are connected to RAVANDI-KASHANI, FARHAD
Item TypeName
Academic Article Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Concept Antimetabolites, Antineoplastic
Academic Article Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study.
Academic Article Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Academic Article Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
Academic Article Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
Academic Article A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
Academic Article Fluoropyrimidines: a critical evaluation.
Academic Article Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer.
Academic Article Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.
Academic Article Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Academic Article Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Academic Article Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.
Academic Article Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Academic Article Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia.
Academic Article Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
Academic Article Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
Academic Article Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
Academic Article Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
Academic Article Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Academic Article Decitabine in the treatment of myelodysplastic syndromes.
Academic Article Decitabine in older adults with acute myeloid leukemia: why was the dream broken?
Academic Article Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
Academic Article Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
Academic Article Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Search Criteria
  • Antimetabolites Antineoplastic